Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Canadian (TSX) Healthcare Sector Analysis

UpdatedApr 14, 2026
DataAggregated Company Financials
Companies123
  • 7D-0.1%
  • 3M-7.1%
  • 1Y35.7%
  • YTD-3.8%

The Healthcare industry has been flat over the last week, but Green Thumb Industries has lost 6.6%. As for the the longer term, the industry is up 35% over the past 12 months. Earnings are forecast to grow by 45% annually.

Sector Valuation and Performance

Has the Canadian Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 14 Apr 2026CA$32.8bCA$17.5b-CA$1,894,081,045.2823.9x-17.3x1.9x
Thu, 12 Mar 2026CA$32.6bCA$17.7b-CA$2,143,919,439.5915.5x-15.2x1.8x
Sat, 07 Feb 2026CA$32.1bCA$17.5b-CA$2,187,215,660.0121.2x-14.7x1.8x
Mon, 05 Jan 2026CA$35.8bCA$19.2b-CA$2,214,096,271.2421.9x-16.2x1.9x
Wed, 03 Dec 2025CA$32.2bCA$19.3b-CA$2,191,673,157.6618x-14.7x1.7x
Fri, 31 Oct 2025CA$36.6bCA$19.4b-CA$2,324,847,135.4238.4x-15.8x1.9x
Sun, 28 Sep 2025CA$35.3bCA$19.5b-CA$2,319,984,217.3939.1x-15.2x1.8x
Tue, 26 Aug 2025CA$35.1bCA$20.0b-CA$2,839,678,080.0039.2x-12.4x1.8x
Thu, 24 Jul 2025CA$28.5bCA$19.5b-CA$2,770,760,849.5921.6x-10.3x1.5x
Sat, 21 Jun 2025CA$27.0bCA$19.6b-CA$2,806,037,906.5620.8x-9.6x1.4x
Mon, 19 May 2025CA$26.6bCA$18.1b-CA$2,473,566,202.3722.1x-10.7x1.5x
Wed, 16 Apr 2025CA$24.5bCA$19.7b-CA$2,835,098,579.5925.2x-8.7x1.2x
Fri, 14 Mar 2025CA$26.7bCA$20.1b-CA$2,908,824,002.0521.6x-9.2x1.3x
Sun, 09 Feb 2025CA$29.1bCA$19.8b-CA$2,493,697,624.3123.9x-11.7x1.5x
Tue, 07 Jan 2025CA$29.8bCA$19.8b-CA$2,726,693,891.5627.3x-10.9x1.5x
Thu, 05 Dec 2024CA$30.0bCA$19.7b-CA$2,884,025,154.6723.6x-10.4x1.5x
Sat, 02 Nov 2024CA$33.5bCA$19.6b-CA$2,991,625,827.2319.9x-11.2x1.7x
Mon, 30 Sep 2024CA$32.7bCA$19.2b-CA$2,959,562,533.1121.6x-11.1x1.7x
Wed, 28 Aug 2024CA$32.6bCA$19.1b-CA$3,003,993,829.2322.1x-10.8x1.7x
Fri, 26 Jul 2024CA$33.7bCA$19.3b-CA$3,681,402,936.5721.1x-9.2x1.8x
Sun, 23 Jun 2024CA$32.2bCA$19.3b-CA$3,775,996,010.0017.4x-8.5x1.7x
Tue, 21 May 2024CA$37.3bCA$19.4b-CA$4,055,463,399.0616.1x-9.2x1.9x
Thu, 18 Apr 2024CA$36.0bCA$19.5b-CA$4,079,629,268.1314.2x-8.8x1.8x
Sat, 16 Mar 2024CA$31.2bCA$19.3b-CA$4,055,002,677.4112.7x-7.7x1.6x
Mon, 12 Feb 2024CA$34.8bCA$19.1b-CA$7,362,480,316.2815.8x-4.7x1.8x
Wed, 10 Jan 2024CA$34.6bCA$20.0b-CA$7,667,118,537.0010.9x-4.5x1.7x
Fri, 08 Dec 2023CA$34.8bCA$20.1b-CA$7,735,001,987.0016.1x-4.5x1.7x
Sun, 05 Nov 2023CA$31.1bCA$20.0b-CA$8,370,106,836.0017.1x-3.7x1.6x
Tue, 03 Oct 2023CA$35.0bCA$20.0b-CA$8,397,506,622.0017.5x-4.2x1.8x
Thu, 31 Aug 2023CA$31.1bCA$20.5b-CA$8,906,713,501.0017.6x-3.5x1.5x
Sat, 29 Jul 2023CA$30.1bCA$20.6b-CA$10,788,216,340.0018.6x-2.8x1.5x
Mon, 26 Jun 2023CA$30.0bCA$20.5b-CA$10,620,150,612.0019.4x-2.8x1.5x
Wed, 24 May 2023CA$30.8bCA$20.8b-CA$11,622,798,834.0014.7x-2.6x1.5x
Fri, 21 Apr 2023CA$31.1bCA$21.6b-CA$11,316,753,038.0016.2x-2.7x1.4x
Price to Earnings Ratio

-2.7x


Total Market Cap: CA$31.1bTotal Earnings: -CA$11,316,753,038.00Total Revenue: CA$21.6bTotal Market Cap vs Earnings and Revenue0%0%0%
Canadian Healthcare Sector Price to Earnings3Y Average -9.4x202420252026
Current Industry PE
  • Investors are optimistic on the Canadian Healthcare industry, and appear confident in long term growth rates.
  • The 3-year average PS ratio of 1.6x is lower than the industry's current PS ratio of 1.9x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 6.7% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the Canadian Healthcare sector?

CA Market2.40%
Healthcare-0.096%
Biotech7.60%
Healthtech3.92%
Healthcare Services0.83%
Medical Equipment-1.80%
Life Sciences-2.28%
Pharma-2.68%
Industry PE
  • Investors are most optimistic about the Healthcare Services industry which is trading above its 3-year average PE ratio of 2.4x.
    • Analysts are expecting annual earnings growth of 46.5%, which is higher than its past year's earnings growth of 22.2% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthtech industry, expecting annual earnings growth of 80% over the next 5 years.
  • However this is lower than its past earnings growth rate of 104% per year.
  • In contrast, the Biotech industry is expected to see its earnings decline by 6.0% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
CSH.UN Chartwell Retirement ResidencesCA$21.14-0.3%
CA$128.4m		31.5%PE232.9x
EXE ExtendicareCA$29.434.6%
+CA$121.9m		127.4%PE28.8x
DRUG Bright Minds BiosciencesCA$116.1811.6%
+CA$117.9m		161.5%PB12.7x
SIA Sienna Senior LivingCA$22.801.2%
+CA$99.7m		41.0%PE54.3x
MSCL Satellos BioscienceCA$10.0325.8%
+CA$42.9m		26.6%PB5.5x

Latest News

SIA
CA$22.80
Sienna Senior Living
7D
1.2%
1Y
41.0%
CSH.UN
CA$21.14
Chartwell Retirement Residences
7D
-0.3%
1Y
31.5%
WEED
CA$1.50
Canopy Growth
7D
7.1%
1Y
4.9%

WEED: Everyday Brand Launch And Equity Raise Will Support Future Upside

Analysts have adjusted their CA$ price target on Canopy Growth to reflect updated views on long term revenue growth, profit margin assumptions, and a lower projected future P/E multiple. This has resulted in a slightly different outlook than before.
EXE
CA$29.43
Extendicare
7D
4.6%
1Y
127.4%
VREO
CA$0.56
Vireo Growth
7D
-3.4%
1Y
9.8%
TRUL
CA$8.71
Trulieve Cannabis
7D
-3.9%
1Y
88.9%

TRUL: Higher Margin Profile And Rich Future P/E May Support Repricing

Analysts have lifted their fair value estimate for Trulieve Cannabis to CA$20.36 from CA$19.53, citing updated assumptions that reflect more conservative revenue growth, a higher profit margin profile, and a very large future P/E multiple that aligns with recent Street research patterns of recalibrating price targets while keeping core views intact. Analyst Commentary Street research across sectors shows a pattern of price target resets that keep long term theses largely intact, and this context helps frame how to read the updated fair value for Trulieve Cannabis.
CL
CA$1.26
Cresco Labs
7D
-10.0%
1Y
50.0%

CL: Revised Outlook Will Support Future Upside From Speculative Buy Rating

Analysts have reduced their price target on Cresco Labs to CA$2.25 from CA$2.50, citing updated assumptions regarding fair value, discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts have adjusted their view on Cresco Labs by trimming the price target to CA$2.25 from CA$2.50 while maintaining a Speculative Buy stance, which reflects both perceived upside potential and meaningful execution risk.
TSND
CA$0.88
TerrAscend
7D
-10.2%
1Y
144.4%

TSND: New Brand Partnership And Share Buyback Will Support Future Upside

Analysts have nudged their TerrAscend price target modestly higher to reflect updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E. What's in the News TerrAscend announced the official launch of TYSON 2.0 products in Pennsylvania and Maryland, covering premium flower and high potency vape products under its exclusive partnership with the brand (Key Developments).
GTII
CA$9.30
Green Thumb Industries
7D
-5.8%
1Y
32.3%
EDT
CA$1.38
Spectral Medical
7D
-6.1%
1Y
86.5%
CURA
CA$3.32
Curaleaf Holdings
7D
-2.1%
1Y
199.1%

CURA: Domestic Stabilization Efforts Will Support Bullish Re Rating

Analysts now see Curaleaf's fair value drifting slightly higher, even as the average Street price target edges down from CA$6.00 to CA$5.50. They cite recent sales results and efforts to steady the core business while keeping international growth in focus.
MSCL
CA$10.03
Satellos Bioscience
7D
25.8%
1Y
26.6%
PRN
CA$8.51
Profound Medical
7D
-6.3%
1Y
27.6%
HBP
CA$1.96
Helix BioPharma
7D
29.8%
1Y
151.3%
AIRX
CA$7.01
Redwood AI
7D
18.8%
1Y
n/a
DRUG
CA$116.18
Bright Minds Biosciences
7D
11.6%
1Y
161.5%